Innovative drug sector's cardiac tonic! Wells Fargo & Company bets on Arcellx (ACLX.US) to reshape the landscape of multiple myeloma treatment, predicting that the stock price will rise by over 50%.

Wall Street financial giant Wells Fargo & Company has initiated coverage and set a target price for the American biotech newcomer Arcellx (ACLX.US), giving it an "overweight" rating. They stated that the experimental CAR-T therapy "anito-cel" for multiple myeloma is a "future pillar" in the management system for this blood cancer, and will completely reshape the landscape of myeloma treatment in the future. Even more significantly, Wells Fargo & Company's bullish target price for Arcellx can be seen as a major booster shot for the global innovative drug sector, which is currently in a consolidation phase. Wells Fargo & Company has set a target price of $100 for Arcellx - meaning a potential upside of 53% from Monday's closing price in the eyes of Wells Fargo & Company. Arcellx's stock performance has been poor this year, with a decline of over 15% year-to-date, significantly underperforming the S&P 500 index. Senior analyst Yanan Zhu from Wells Fargo & Company stated that he believes "based on its attractive efficacy and safety features compared to competitors, anito-cel has the potential to expand and dominate the BCMA CAR-T market for multiple myeloma at the 4L and above levels, as opposed to currently approved competitive products." He also added that he expects this treatment to become widely adopted once it officially hits the market in 2026. The analyst pointed out that anito-cel is expected to receive formal approval for second-line treatment in 2028, or possibly earlier, which will significantly drive sales towards a stronger growth trajectory. Arcellx is collaborating with Kite Pharma to develop anito-cel, which is owned by the American healthcare leader Gilead Sciences, Inc. (GILD.US). Analyst Yanan Zhu predicts that peak sales in the fourth-line (4L) field could reach $1.6 billion (with approximately $690 million going to Arcellx) and could reach around $3.8 billion after approval for second-line and above (second-line+) levels (with approximately $1.5 billion going to Arcellx). Despite the strong performance of recent phase 3 clinical trial data for Johnson & Johnson's Tecvayli (teclistamab) and Darzalex (daratumumab) used in combination for multiple myeloma, Wells Fargo & Company analyst Zhu still points out that approximately 30% of patients at the second-line level show extreme resistance to Darzalex, making them ineligible for the Tec-Dara combination. anito-cel - potentially disrupting the landscape of myeloma treatment Arcellx (Nasdaq stock code: ACLX) is a clinical-stage biotech company whose core business is developing innovative cell therapy products for cancer (and extending to some autoimmune directions) based on its proprietary D-Domain technology platform. The company is considered a newcomer/important player in the clinical late stage of the cell therapy race, but its commercial expansion prospects heavily depend on the potential approval and market launch of its innovative drug product line under investigation, such as the official regulatory approval and market rollout of its core innovative drug product anito-cel. Anito-cel (anitocabtagene autoleucel, formerly known as CART-ddBCMA) is a self-targeted CAR-T cell therapy targeting BCMA for relapsed/refractory multiple myeloma; developed and commercialized in collaboration with Kite Pharma (a subsidiary of Gilead under Gilead). In the eyes of renowned analysts from sell-side institutions like Wells Fargo & Company, anito-cel has the potential to completely disrupt the current multiple myeloma treatment market landscape. The core mechanism of anito-cel remains typical CAR-T logic: reengineering patient T cells ex vivo to express chimeric antigen receptors that recognize BCMA (a common target on myeloma cells); upon reinfusion, CAR-T cells identify and kill myeloma cells. However, the differentiation of anito-cel enables the drug to have a higher response rate and relative controllability in terms of safety. Anito-cel is based on Arcellx's new, compact D-Domain binding domain as a key component (considered a design innovation). The differentiated design of anito-cel uses Arcellx's D-Domain (a small, stable binding domain) as the "recognition head." Materials from Kite/Gilead claim that it can achieve higher CAR expression and less/avoidance of "tonic signaling" and is designed for faster release after binding to the target. The goal is to maintain efficacy while reducing the probability of severe immune toxicity (such as severe CRS/ICANS). In the publicly available data from iMMagine-1, CRS is mostly low-grade, and the incidence of ICANS is relatively low. Therefore, if anito-cel, launched by Arcellx as expected in the sell-side market in 2026 for later-line treatment, achieves rapid penetration based on the "efficacy + safety" advantages, it could change the ranking and market share allocation in the field of BCMA-targeted treatments (such as CAR-T and bispecific) for multiple myeloma in the later lines; Wells Fargo & Company's latest sell-side view even calls it one of the future treatment "pillars."